Gilead loses first PrEP patent challenge but vows to defend against HHS lawsuit

Gilead and the U.S. Department of Health and Human Services are locked in a public fight over HIV prevention drug patents, and Gilead has lost the first round. A review board at the U.S. Patent & Trademark Office opted not to take up the company's challenge, but Gilead says it'll keep fighting.